Bone marrow conditioning program

Prior to undergoing haematopoietic stem cell transplantation (HSCT) for the treatment of haematologic malignancies (blood cancers), patients undergo a bone marrow conditioning (BMC) treatment. The current standard of care typically requires BMC with multi-drug chemotherapy regimens. However, these regimens are highly toxic, and patients may not tolerate treatment. This creates an important unmet medical need for more tolerable BMC regimens.

We are exploring the potential utility of targeted radiation in BMC to ablate bone marrow as part of a pre-conditioning regimen for bone marrow transplantation, novel stem cell therapies and gene therapies – each of which requires conditioning prior to treatment.

Telix’s bone marrow conditioning portfolio targets cluster of differentiation 66 (CD66), a well-validated receptor expressed on specific types of immune or blood cells and a potential target for conditioning radiopharmaceuticals.

Bone marrow conditioning worldwide


number of first haematopoietic stem cell transplantations performed in 2019 worldwide

11 months

median overall survival for SALA from diagnosis


countries where TLX66-CDx is currently approved and marketed as Scintimun®